BRISTOL-MYERS SQUIBB COMPANY Current Liabilities
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Current Liabilities of $18.66 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-07-30
- 2026-06-30: Liabilities, Current $18.66B.
- 2026-03-31: Liabilities, Current $19.16B.
- 2025-12-31: Liabilities, Current $23.42B.
- 2025-09-30: Liabilities, Current $28.14B.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $18.66B 10-Q · filed 2026-07-30 |
| 2026-03-31 | $19.16B 10-Q · filed 2026-04-30 |
| 2025-12-31 | $23.42B 10-Q · filed 2026-07-30 |
| 2025-09-30 | $28.14B 10-Q · filed 2025-10-30 |
| 2025-06-30 | $27.53B 10-Q · filed 2025-07-31 |
| 2025-03-31 | $24.07B 10-Q · filed 2025-04-24 |
| 2024-12-31 | $23.77B 10-K · filed 2026-02-11 |
| 2024-09-30 | $22.64B 10-Q · filed 2024-10-31 |
| 2024-06-30 | $23.27B 10-Q · filed 2024-07-26 |
| 2024-03-31 | $25.82B 10-Q · filed 2024-04-25 |
| 2023-12-31 | $22.26B 10-K · filed 2025-02-12 |
| 2023-09-30 | $23.46B 10-Q · filed 2023-10-26 |
| 2023-06-30 | $20.15B 10-Q · filed 2023-07-27 |
| 2023-03-31 | $19.09B 10-Q · filed 2023-04-27 |
| 2022-12-31 | $21.89B 10-K · filed 2024-02-13 |
| 2022-09-30 | $18.93B 10-Q · filed 2022-10-26 |
| 2022-06-30 | $20.91B 10-Q · filed 2022-07-27 |
| 2022-03-31 | $22.82B 10-Q · filed 2022-04-29 |
| 2021-12-31 | $21.87B 10-K · filed 2023-02-14 |
| 2021-09-30 | $21.46B 10-Q · filed 2021-10-27 |
| 2021-06-30 | $18.99B 10-Q · filed 2021-07-28 |
| 2021-03-31 | $17.33B 10-Q · filed 2021-04-29 |
| 2020-12-31 | $19.08B 10-K · filed 2022-02-09 |
| 2020-09-30 | $20.46B 10-Q · filed 2020-11-05 |
| 2020-06-30 | $23.42B 10-Q · filed 2020-08-06 |
| 2020-03-31 | $19.23B 10-Q · filed 2020-05-07 |
| 2019-12-31 | $18.30B 10-K · filed 2021-02-10 |
| 2019-09-30 | $10.49B 10-Q · filed 2019-10-31 |
| 2019-06-30 | $9.71B 10-Q · filed 2019-07-25 |
| 2019-03-31 | $8.84B 10-Q · filed 2019-04-25 |
| 2018-12-31 | $10.65B 10-K · filed 2020-02-24 |
| 2018-09-30 | $9.69B 10-Q · filed 2018-10-25 |
| 2018-06-30 | $9.88B 10-Q · filed 2018-07-26 |
| 2018-03-31 | $9.62B 10-Q · filed 2018-04-26 |
| 2017-12-31 | $9.56B 10-K · filed 2019-02-25 |
| 2017-09-30 | $9.44B 10-Q · filed 2017-10-26 |
| 2017-06-30 | $9.02B 10-Q · filed 2017-07-27 |
| 2017-03-31 | $8.49B 10-Q · filed 2017-04-27 |
| 2016-12-31 | $8.84B 10-K · filed 2018-02-13 |
| 2016-09-30 | $9.00B 10-Q · filed 2016-10-27 |
| 2016-06-30 | $7.88B 10-Q · filed 2016-07-28 |
| 2016-03-31 | $7.60B 10-Q · filed 2016-04-28 |
| 2015-12-31 | $8.02B 10-K · filed 2017-02-21 |
| 2015-09-30 | $7.16B 10-Q · filed 2015-10-27 |
| 2015-06-30 | $7.43B 10-Q · filed 2015-07-23 |
| 2015-03-31 | $7.69B 10-Q · filed 2015-04-28 |
| 2014-12-31 | $8.46B 10-K · filed 2016-02-12 |
| 2014-09-30 | $8.10B 10-Q · filed 2014-10-24 |
| 2014-06-30 | $7.80B 10-Q · filed 2014-07-24 |
| 2014-03-31 | $7.52B 10-Q · filed 2014-04-29 |
| 2013-12-31 | $12.44B 10-K · filed 2015-02-13 |
| 2013-09-30 | $8.28B 10-Q · filed 2013-10-23 |
| 2013-06-30 | $8.35B 10-Q · filed 2013-07-25 |
| 2013-03-31 | $8.41B 10-Q · filed 2013-04-25 |
| 2012-12-31 | $8.28B 10-K · filed 2014-02-14 |
| 2012-09-30 | $8.20B 10-Q · filed 2012-10-24 |
| 2012-06-30 | $6.99B 10-Q · filed 2012-07-25 |
| 2012-03-31 | $7.21B 10-Q · filed 2012-04-26 |
| 2011-12-31 | $7.78B 10-K · filed 2013-02-15 |
| 2011-09-30 | $7.31B 10-Q · filed 2011-10-27 |
| 2011-06-30 | $7.41B 10-Q · filed 2011-07-28 |
| 2011-03-31 | $6.75B 10-Q · filed 2011-04-28 |
| 2010-12-31 | $6.74B 10-K · filed 2012-02-17 |
| 2010-09-30 | $6.28B 10-Q · filed 2010-10-26 |
| 2010-06-30 | $5.91B 10-Q · filed 2010-07-22 |
| 2010-03-31 | $6.02B 10-Q · filed 2010-04-29 |
| 2009-12-31 | $6.31B 10-K · filed 2011-02-18 |
| 2009-09-30 | $7.39B 10-Q · filed 2009-10-22 |
| 2009-06-30 | $6.74B 10-Q · filed 2009-07-23 |
| 2008-12-31 | $6.71B 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |